Characterization of monocyte-derived dendritic cells from cats infected with feline immunodeficiency virus

Fuminori Mizukoshi1, Kenji Baba, Hiroshi Horiuchi

  • 1Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

Insights

Monocytes from FIV-infected cats can differentiate into functional dendritic cells (DCs). These cells retain antigen-presenting capabilities, suggesting potential for DC-based immunotherapy against feline immunodeficiency virus (FIV).

Area of Science:

  • Immunology
  • Veterinary Medicine
  • Cell Biology

Background:

  • Dendritic cells (DCs) are crucial antigen-presenting cells (APCs) for initiating immune responses.
  • Feline immunodeficiency virus (FIV) infection poses a significant challenge in feline health.
  • Developing effective immunotherapies for FIV is essential.

Purpose of the Study:

  • To characterize dendritic cells (DCs) derived from FIV-infected cats.
  • To compare these DCs with those from healthy controls for potential immunotherapy applications.
  • To assess the functionality of DCs in the context of FIV infection.

Main Methods:

  • Derivation of DCs from adherent peripheral blood mononuclear cells.
  • Cultivation of DCs using recombinant feline interleukin-4, granulocyte macrophage colony-stimulating factor, and autologous plasma.
  • Analysis of cell morphology, surface phenotype (CD1c, CD80, MHC class II, CD1a), endocytosis, and mixed leukocyte reaction (MLR).

Main Results:

  • Monocyte-derived DCs from both FIV-infected and healthy cats exhibited dendritic morphology and expressed APC markers (CD1c, CD80, MHC class II).
  • Variable CD1a expression was observed in DCs from FIV-infected cats, unlike controls.
  • DCs from FIV-infected cats maintained dextran uptake via the mannose receptor and showed MLR activity.

Conclusions:

  • Monocytes from FIV-infected cats can differentiate into functional DCs.
  • These feline DCs possess APC-like functions and are suitable for immunotherapy.
  • DC-based immunotherapy is a promising strategy for managing FIV infection.